Why the study?
Although soluble junctional adhesion molecule-A (sJAM-A) is elevated in atherosclerotic cardiovascular disease, its role in arteriosclerosis obliterans and platelet hyperreactivity remained unclear.
Population
Arteriosclerosis obliterans patients and controls
Comparison
Arteriosclerosis obliterans patients vs controls, and in vitro sJAM-A exposure with vs without neutralizing antibodies
Design
Clinical observational cohort and in vitro mechanistic study
Follow-up
1 year
Answers are grounded in this paper and cite their sources.
Reveals that soluble JAM-A triggers platelet activation via homodimerization and predicts reintervention in arteriosclerosis obliterans, suggesting a self-amplifying target for atherosclerosis.
Background and Aims Although soluble junctional adhesion molecule-A (sJAM-A) is elevated in atherosclerotic cardiovascular disease, its role in arteriosclerosis obliterans (ASO) and platelet hyperreactivity remains unclear. We aimed to evaluate the clinical prognostic value of sJAM-A and elucidate its platelet-activating mechanisms. Methods Plasma sJAM-A, CXCL4, CCL2, and CCL5 were measured by ELISA in ASO patients and controls, with 1-year reintervention tracked. Flow cytometry was used to evaluate platelet activation, surface JAM-A expression, and sJAM-A binding. In vitro, sJAM-A-induced platelet activation was evaluated with or without neutralizing antibodies, and ADAM17/10-mediated sJAM-A shedding was assessed. sJAM-A–JAM-A interactions and downstream signaling cascades were dissected using His-tag pull-down and Western blotting. Results Plasma sJAM-A and chemokines were elevated in ASO patients, accompanied by heightened platelet reactivity. Elevated plasma sJAM-A (>5.65 ng/mL) independently predicted an increased risk of target vessel reintervention. In vitro, sJAM-A lowered the activation threshold, enhancing agonist-induced platelet aggregation, granule secretion, and outside-in signaling, which was abolished by a neutralizing anti-JAM-A antibody. Activated platelets shed sJAM-A in an ADAM17/10-dependent manner. Mechanistically, sJAM-A engaged membrane-bound JAM-A to facilitate homodimer formation, triggering Src-PI3K-Akt signaling. Conclusions Elevated plasma sJAM-A serves as an independent predictor of reintervention in ASO. Shed sJAM-A amplifies platelet hyperreactivity via homophilic JAM-A interaction and Src-PI3K-Akt signaling. Activated platelets in turn shed sJAM-A, potentially forming a self-amplifying loop. Thus, sJAM-A represents both a prognostic biomarker and a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: